Phase IIb Clinical Trial for the Efficacy and Safety by CU01-1001 for 24 Weeks in Type 2 DM Patients With Albuminuria
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 240 participants.
Also called NCT05718375
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 240 participants
- Sponsor
- Curacle Co., Ltd.
- Registry
-
NCT05718375
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT05718375. Randomized; triple masking; primary purpose treatment. Start 2023-02-14 (actual); primary completion 2025-11-12 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Phase IIb Clinical Trial for the Efficacy and Safety by CU01-1001 for 24 Weeks in Type 2 DM Patients With Albuminuria
- Condition
- Diabetic Nephropathies
- Intervention (Drug)
- CU01-1001
- Intervention (Drug)
- Placebo
- Lead sponsor
- Curacle Co., Ltd.
Record details
- Record id
cardio:ct-nct05718375- Content hash
45c89abb9ef466e0e90ed64fe94f5b0109cf257c8f79f670dc3ca235cc94ff37